ANZCTR search results

This trial aims to determine the effects of short-term intranasal oxytocin intervention on emotional processing in individuals diagnosed with Frontotemporal Dementia . We further wish to evaluate whether administration of oxytocin has an effect on carer-burden using standardised questionnaires to capture changes in patient-carer relationships. Who is it for? Patients between the ages of 40 to 75 years, who have been diagnosed with behavioural variant frontotemporal dementia, semantic dementia or progressive non-fluent aphasia, and have a carer who will be able to live with them for the duration of the study are eligible to participate. Study details Patients who have previously been recruited by the Frontier Research Clinic for the 'Clinical Assessment for Ageing and Neurodegeneration Research' study will be contacted to participate in this four-week clinical trial using oxytocin nasal spray. Patients will undergo clinical and neuropsychological assessments at their initial visit, followed by assessments of emotion, cognition, carer-burden and blood sampling at further visits. Patients will be randomised to receive either placebo or oxytocin for one-week, then be off any intervention for one week followed by the counter-intervention for a one-week period. Experimental tasks and clinical assessments will be performed at the Brain and Mind Centre on appropriate visit days and study compliance will be monitored using a drug diary and help from the caregiver.

The NINJA clinical trial aims to compare two emerging schedules of radiotherapy in the treatment of prostate cancer. Who is it for? You may be eligible for this study if you are an adult male over the age of 18 who has been diagnosed with intermediate or high risk prostate cancer . Study details Participants will be randomly assigned to one of two radiotherapy schedules as part of this study. In schedule 1 (called Sterotactic Body Radiotherapy) participants will receive 5 radiotherapy treatments over 2 weeks and in schedule 2 (called Virtual High Dose Rate Boost) participants will receive Sterotactic Body Radiotherapy delivered in 2 treatments over 1 week followed by 12 treatments of conventional external beam radiotherapy over 2 and a half weeks. A blood test will be collected at the initial assessment, 6 weeks after radiotherapy and 6 monthly for a period of 5 years. Questionnaires will completed at the initial assessment, 6 weeks after radiotherapy and at 2 and 5 years. It is hoped that this research will potentially improve the accuracy and quality of radiotherapy treatment in prostate cancer.

This clinical trial aims to determine why the positive findings in lung function and exercise tolerance occur following bronchoscopic lung volume reduction therapy of Chronic Obstructive Pulmonary Disease (COPD). It is thought that these improvements are a result of changes in lung, heart, and vasculature physiology following this treatment. This trial will investigate all three areas, using a combination of Cardiopulmonary Exercise Testing (CPET), Echocardiogram, Cardiac Magentic Resonance Imaging, Nuclear Medicine SPECT scanning, and measurement of blood serum biomarkers. The results of this study may assist in the future identification and selection of patients for this procedure, thereby improving their overall care and management.

BTX 1308 contains the active pharmaceutical ingredient, cannabidiol in a topical liquid formulation, and is being developed for the treatment of psoriasis vulgaris by Botanix Pharmaceuticals Limited. CBD is a member of a broader family of compounds known as cannabinoids, a class of compounds originally derived from the cannabis sativa plant. CBD is chemically synthesized under Good Manufacture Practices (GMP) for use in this study.The objective of this study is to assess preliminary safety, tolerability, and activity of various formulations and concentrations of BTX 1308 in subjects with mild to moderate, stable, plaque-type psoriasis. This will be a single-center, vehicle and comparator-controlled, evaluator-blinded study in volunteers aged 18 years and over. Participants will receive 4 treatments, across up to 3 comparable psoriasis plaques. BTX 1308 – 1 5% BTX 1308 – 3 20% BTX 1308 Vehicle Approved psoriasis product – Betnovate® (betamethasone valerate) Ointment 0.1% Safety and cutaneous tolerability will be assessed by the collection and review of AEs and application site review, laboratory parameters throughout the duration of the trial. Efficacy assessments will include measurement of the thickness of the psoriatic inflammatory infiltrate using sonography. Photography of the treated area will be conducted for all participants. Participants will remain in follow up until 19 days following the first application of investigational product.

This study is investigating whether the presence of therapy dogs in speech pathology sessions with preschool children has a positive impact on language and social communication, It is hypothesised that the use of therapy dogs will lead to further gains in these children's language development, participation and engagement with therapy sessions.

This project is investigating how a home-based family caregiver directed music intervention impacts the behavioural and psychological symptoms of dementia, the levels of depression in person living with dementia and their family caregiver, and their quality of life. It is part of larger international study involving European investigators. The project will study the impact of music on wellbeing for 198 older Australians (99 dyads) over a 6-month period, with a total sample size of 495 dyads across the 5 countries. Each dyad will be randomly assigned to either a music intervention, a reading intervention (active control) or standard care. Over the 6-month period, we will be collecting a range of data that will help us understand whether music has or has an effect on participants' mood, quality of life, and symptoms of dementia. Moreover, we will be asking carers to complete measures about their own wellbeing to help us understand the impact of the music intervention has on caregivers' wellbeing and burden.

The purpose of this study is to assess the feasibility and acceptability of a pharmacist and nurse-led intervention to help management of medication in people taking ibrutinib. Who is it for? You may be eligible for this study if you are an adult who has been diagnosed with chronic lymphocytic leukaemia, small lymphocytic lymphoma, mantle cell lymphoma or walenstrom’s macroglobulinaemia and are scheduled to commence ibrutinib as part of your usual care. Study details Participants will be randomly allocated to one of two groups. One group will receive usual care including standard medication management. The other group will receive a face-to-face consultation with a pharmacist to discuss their medication, and complete five phone calls with a nurse over 12 weeks to assist with taking medication as prescribed by their doctor. Participants in the second group will also use a phone app that will provide daily medication reminders, and access to advice on how to manage any side-effects. All participants will also complete questionnaires relating to their health and complete routine blood tests. It is hoped that this research will help provide an effective way of managing medications during cancer treatment.

This study aims to compare the quality of twelve different surgical marking pens available in Australia. Quality will be defined based on visibility of ink after surgical wash, as well as sterility of pen tips based on swab cultures. The study will be performed on six medical student volunteers. Lines will be drawn on the volunteers' thighs using marking pens, and the limbs will be washed with one of four different surgical preparation liquids. The ink visibility will be assessed using digital photographs on software (Photoshop). The pen tips will be swabbed after use for culture of organisms in a pathology laboratory.

The purpose of this study is to investigate whether it is possible to treat patients who are receiving head/neck cancer radiotherapy with a drug called pregabalin, targeting pain before it has arisen. Who is it for? You may be eligible for this study if you are aged over 18 and are receiving curative radiotherapy to the head and neck area to treat squamous cell carcinoma Study details Participants in this study will be randomised (by chance) into one of two groups. One group will continue standard care, including radiotherapy treatment with standard pain-killers to treat the radiotherapy-related pain. The other group will take a medication called pregablin during the course of their radiotherapy. Pregabalin will be prescribed in addition to the standard pain-killers used to treat radiotherapy-related pain. All participants will receive standard of care radiotherapy and will undergo the routine tests required for treatment including scans before treatment and blood tests once a week whilst having radiotherapy. In addition, all patients in the trial will be asked to complete weekly pain questionnaires during radiotherapy and swallowing questionnaires at 6 weeks, 12 weeks, 24 weeks and 52 weeks after completion of radiotherapy. It is hoped this research will provide evidence to support a larger study to see Pregablin reduces the swallowing pain that is often experienced during head and neck radiotherapy.

Cool Kids - Taking Control is an online self-help program that is designed to help children who report been the target of bullying and who also report high levels of anxiety symptoms. The program is delivered over the internet and involves eight lessons for parents to work through with their child at home. As the child’s Coach, the parent role is to teach and support the child to learn how to use their new Cool Kids skills. The primary aim of this study is to evaluate the CKTC online program to determine whether it is more effective in reducing bullying victimisation and anxiety in children compared to treatment-as-usual.